Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07510815 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma

Name: Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma — clinical trial record (NCT07510815)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUAL-MESO-NK

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-03-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

Mesothelioma

178 trials monitored

See 13 trials at risk

This example study evaluates locoregional allogeneic dual-target mesothelin/FAP CAR-NK cells in adults with unresectable, recurrent, or refractory pleural or peritoneal mesothelioma. Eligible participants must have central confirmation of MSLN-positive tumor cells and FAP-positive tumorassociated stroma. The phase 1 portion defines the recommended phase 2 dose and schedule, and the phase 2 expansion explores preliminary antitumor activity, persistence, and biomarker response in pleural and peritoneal disease cohorts.

Trial Details

NCT Number	NCT07510815
Lead Sponsor	Beijing Biotech
Conditions	Malignant Pleural Mesotheliomas
Enrollment	36 participants
Start Date	2026-03-02
Primary Completion	2027-03-14 (estimated)
Study Completion	2028-04-17 (estimated)
Updated on ClinicalTrials.gov	2026-04-06